Greenbrook
TMS Therapy for Depression | Depression Treatment | Greenbrook TMS. Learn more
Launch date
Employees
Market cap
€1.9m
Enterprise valuation
€98m (Public information from Feb 2024)
Share price
$0.0088 GBNH
Tysons Virginia (HQ)
Financials
Estimates*
USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Revenues | 21.3m | 35.7m | 43.1m | 52.2m | 69.1m | 73.8m | 89.4m |
% growth | 54 % | 68 % | 21 % | 21 % | 32 % | 7 % | 21 % |
EBITDA | (4.6m) | (6.6m) | (11.1m) | (16.4m) | (19.2m) | (28.8m) | 2.0m |
% EBITDA margin | (21 %) | (18 %) | (26 %) | (31 %) | (28 %) | (39 %) | 2 % |
Profit | (5.0m) | (15.9m) | (29.7m) | (24.8m) | (61.7m) | (48.9m) | - |
% profit margin | (23 %) | (45 %) | (69 %) | (47 %) | (89 %) | (66 %) | - |
EV / revenue | 3.3x | 2.7x | 3.6x | 2.1x | 2.3x | 1.9x | 0.1x |
EV / EBITDA | -15.6x | -14.7x | -14.1x | -6.7x | -8.2x | -4.8x | 6.3x |
R&D budget | <1m | 1.5m | <1m | <1m | <1m | - | - |
R&D % of revenue | 2 % | 4 % | 1 % | 2 % | 1 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | N/A | $75.0m | Post IPO Debt |
* | $2.0m | Post IPO Debt | |
* | N/A | $750k | Post IPO Convertible |
* | N/A | $6.3m | Private Placement VC |
* | $1.5m | Post IPO Debt | |
* | $2.0m | Post IPO Debt | |
* | $2.5m | Post IPO Debt | |
* | $5.3m | Post IPO Debt | |
* | $1.5m | Post IPO Debt | |
* | N/A | Acquisition | |
Total Funding | €5.7m |
Recent News about Greenbrook
EditMore about Greenbrook
EditGreenbrook TMS NeuroHealth is the nation’s leading provider of Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and Obsessive Compulsive Disorder. Since 2011, we’ve provided more than 320,000 life-changing TMS treatments to over 9,000 patients. Learn more at greenbrooktms.com
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Greenbrook
EditACQUISITION by Greenbrook Sep 2021
ACQUISITION by Greenbrook May 2022